- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01161940
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
July 13, 2010 updated by: Dr. Reddy's Laboratories Limited
A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Fasting Conditions
This is a bioequivalence study of nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited under fasting conditions
Study Overview
Detailed Description
Open label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, comparative oral bioavailability study in healthy, adult, male human subjects under fasting conditions.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy males between 18 and 55 years of age (inclusive) living in and around Ahmedabad city of western part of India.
- Having a Body Mass Index (BMI) ≥ 18.0 kg/m2 (calculated as weight in kg/ height in m2).
- Have no significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, ECG and X-ray recordings.
- Able to communicate effectively with study personnel. Able to give consent for participation in the trial
Exclusion Criteria:
- Known hypersensitivity or idiosyncratic reaction to nizatidine or other related drugs.
- Any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal, or any other body system.
- Ingestion of a medication at any time in 14 days before the start of the study. In any such case subject selection will be at the discretion of the Principal Investigator/Medical expert/co-investigator.
- Any history or presence of asthma or nasal polyp.
- A recent history of alcoholism (<2years) or of moderate (180 ml/day) alcohol use.
- Smokers, who smoke more than 10 cigarettes/day or those who cannot refrain from smoking during study period.
- The presence of clinically significant abnormal laboratory values during screening.
- Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scan.
- History of psychiatric disorders.
- A history of difficulty with donating blood.
- Donations of blood (1 unit or 450 ml) within 90 days prior to receiving the first dose of study medication. Note: Incase the blood loss is ≤ 200 L, subject may be dosed after completion of 60 days of blood donation).
- A positive hepatitis screen including hepatitis B surface antigen, anti-HCV and anti-HAV antibodies.
- A positive test result for HIV antibody and/or syphilis.
- The receipt of an investigational product or participation in a drug research study within a period of 90 days prior to the first dose of study medication (Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study). (Note: If subject had participated in a study in which blood loss is ≤200 mL, subject can be dosed after completion of 60 days of previous study).
- An unusual diet, for whatever reason (eg., low-sodium), for four weeks prior to receiving the study medication and throughout the subjects, participation in the study. In any such case subject will be at the discretion of the Principal Investigator/Medical expert/Co-investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nizatidine
Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
|
Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
Other Names:
|
Active Comparator: Axid
Axid 300 mg Capsules of Reliant Pharmaceuticals, US
|
Axid 300 mg Capsules of Reliant Pharmaceuticals, US
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence based on Cmax and AUC parameters
Time Frame: 3 Months
|
3 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Charu Gautam, M.D, Lambda Therapeutic Research Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2004
Primary Completion (Actual)
September 1, 2004
Study Completion (Actual)
September 1, 2004
Study Registration Dates
First Submitted
July 13, 2010
First Submitted That Met QC Criteria
July 13, 2010
First Posted (Estimate)
July 14, 2010
Study Record Updates
Last Update Posted (Estimate)
July 14, 2010
Last Update Submitted That Met QC Criteria
July 13, 2010
Last Verified
July 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 090-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Nizatidine
-
University of California, San FranciscoNational Institute of General Medical Sciences (NIGMS)Completed
-
Braintree LaboratoriesCompletedGastroesophageal Reflux Disease | GERD | HeartburnUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
Daewoong Pharmaceutical Co. LTD.Not yet recruiting
-
Seoul National University HospitalDong-A ST Co., Ltd.Not yet recruiting
-
King Saud UniversityCompletedPulmonary Aspiration of Gastric Contents
-
Adil BharuchaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedGastroparesisUnited States
-
Eli Lilly and CompanyCompleted
-
Canadian Network for Observational Drug Effect...Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...CompletedGastroesophageal Reflux Disease (GERD) | Community-acquired PneumoniaCanada